Phase I trial of motexafin gadolinium (MGd) and docetaxel administered at 3-week intervals for advanced solid tumours

Trial Profile

Phase I trial of motexafin gadolinium (MGd) and docetaxel administered at 3-week intervals for advanced solid tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Motexafin gadolinium (Primary) ; Docetaxel
  • Indications Advanced breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Sarcoma
  • Focus Adverse reactions
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 14 May 2007 Status changed from in progress to completed.
    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top